EIDD-1931

• Product Name Alternative:

  β-D-N4-hydroxycytidine; NHC

• UNSPSC Description:

  EIDD-1931 (Beta-d-N4-hydroxycytidine; NHC) is a novel nucleoside analog and behaves as a potent anti-virus agent. EIDD-1931 effectively inhibits the replication activity of venezuelan equine encephalitis virus (VEEV), Chikungunya virus (CHIKV) and hepatitis C virus (HCV)[1].

• Target Antigen:

  Enterovirus; HCV; SARS-CoV; Topoisomerase

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Cell Cycle/DNA Damage

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/beta-d-n4-hydroxycytidine.html

• Purity:

  99.96

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : ≥ 25 mg/mL

• Smiles:

  O=C1N/C(C=CN1[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)=N/O

• Molecular Weight:

  259.22

• References & Citations:

  [1]Urakova N, et al. β-d-N⁴-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome. J Virol. 2018 Jan 17;92(3). pii: e01965-17.|[2]Brenda I Hernandez-Santiago, et al. Metabolism of the anti-hepatitis C virus nucleoside beta-D-N4-hydroxycytidine in different liver cells. Antimicrob Agents Chemother. 2004 Dec;48(12):4636-42|[3]Maryam Ehteshami, et al. Characterization of β-d- N4-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  3258-02-4